Previous close | 0.3000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.1500 |
Strike | 70.00 |
Expiry date | 2024-05-17 |
Day's range | 0.2000 - 0.3000 |
Contract range | N/A |
Volume | |
Open interest | 43 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
On May 14, 2024, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals Inc (NASDAQ:ANIP), executed a sale of 16,669 shares of the company.